(QDEL) Quidel - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 777m USD | Total Return: -63.2% in 12m

Diagnostic Tests, Laboratory Instruments, Immunoassays, Molecular Diagnostics

Total Rating 7

Safety 32

Buy Signal -0.19

Medical Devices
Industry Rotation: +4.2

Market Cap: 777M
Avg Turnover: 24.9M

Risk 3d forecast

Volatility79.2%

VaR 5^th Pctl12.9%

VaR vs Median-0.88%

Reward TTM

Sharpe Ratio-0.98

Rel. Str. IBD0.4

Rel. Str. Peer Group2.2

Character TTM

Beta1.449

Beta Downside1.321

Hurst Exponent0.418

Drawdowns 3y

Max DD88.76%

CAGR/Max DD-0.55

CAGR/Mean DD-0.96

EPS (Earnings per Share)

EPS CAGR: -56.78%
EPS Trend: -72.5%

Last SUE: -2.69
Qual. Beats: -1

Revenue

Rev. CAGR: 0.28%
Rev. Trend: -41.7%

Last SUE: -1.38
Qual. Beats: -1

Warnings

Interest Coverage Ratio -5.3 is critical

Altman Z'' -1.56 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: QDEL Quidel

QuidelOrtho Corporation is a global provider of diagnostic testing solutions, operating through four primary segments: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. The company manufactures and distributes clinical chemistry instruments, immunoassay tests, blood-typing systems, and molecular PCR thermocyclers. Its business model relies on a razor-razorblade strategy, where the placement of diagnostic hardware drives recurring revenue through the sale of proprietary reagents and consumable test kits.

The company serves a diverse client base ranging from high-volume clinical laboratories and blood banks to point-of-care settings like urgent care clinics and pharmacies. Within the Health Care Supplies sector, diagnostic providers face high barriers to entry due to stringent FDA and international regulatory requirements for manufacturing and clinical validation. QuidelOrtho maintains a global footprint with operations across North America, Europe, China, and the Asia Pacific region.

Investors may find more detailed performance metrics and valuation models by exploring the tools available on ValueRay. The firm continues to leverage its 1979 incorporation roots and San Diego headquarters to manage a complex distribution network involving both direct sales and third-party partnerships.

Headlines to Watch Out For

Post-pandemic respiratory testing demand volatility impacts core Point of Care revenue
Synergies from Ortho Clinical merger drive operational efficiency and margin expansion
Lab business growth in emerging markets offsets maturing North American diagnostic sales
Regulatory approval cycles for new molecular diagnostic assays dictate long-term valuation
High debt leverage following major acquisitions increases sensitivity to interest rate shifts

Piotroski VR‑10 (Strict) 2.0

Net Income: -1.21b TTM > 0 and > 6% of Revenue
FCF/TA: -0.01 > 0.02 and ΔFCF/TA -1.81 > 1.0
NWC/Revenue: 15.60% < 20% (prev 7.63%; Δ 7.97% < -1%)
CFO/TA 0.00 > 3% & CFO 6.60m > Net Income -1.21b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.43 > 1.5 & < 3
Outstanding Shares: last quarter (68.2m) vs 12m ago 1.04% < -2%
Gross Margin: 44.96% > 18% (prev 0.47%; Δ 4.45k% > 0.5%)
Asset Turnover: 43.96% > 50% (prev 42.79%; Δ 1.17% > 0%)
Interest Coverage Ratio: -5.35 > 6 (EBITDA TTM -548.8m / Interest Expense TTM 186.4m)

Altman Z'' -1.56

A: 0.07 (Total Current Assets 1.38b - Total Current Liabilities 962.4m) / Total Assets 5.63b
B: -0.19 (Retained Earnings -1.09b / Total Assets 5.63b)
C: -0.16 (EBIT TTM -996.6m / Avg Total Assets 6.05b)
D: -0.29 (Book Value of Equity -1.09b / Total Liabilities 3.78b)
Altman-Z'' Score: -1.56 = D

Beneish M -3.43

DSRI: 0.86 (Receivables 359.9m/437.0m, Revenue 2.66b/2.76b)
GMI: 1.04 (GM 44.96% / 46.94%)
AQI: 0.87 (AQ_t 0.49 / AQ_t-1 0.56)
SGI: 0.96 (Revenue 2.66b / 2.76b)
TATA: -0.22 (NI -1.21b - CFO 6.60m) / TA 5.63b)
Beneish M-Score: -3.43 (Cap -4..+1) = AA

What is the price of QDEL shares? As of May 21, 2026, the stock is trading at USD 11.91 with a total of 1,931,403 shares traded.
Over the past week, the price has changed by +7.78%, over one month by -7.60%, over three months by -47.02% and over the past year by -63.22%.

Is QDEL a buy, sell or hold? Quidel has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy QDEL.

StrongBuy: 3
Buy: 2
Hold: 2
Sell: 1
StrongSell: 0

What are the forecasts/targets for the QDEL price?

Analysts Target Price	17.3	45.3%

Quidel (QDEL) - Fundamental Data Overview as of 16 May 2026

P/E Forward = 7.2254
P/S = 0.2923
P/B = 0.3978
P/EG = 2.0638
Revenue TTM = 2.66b USD
EBIT TTM = -996.6m USD
EBITDA TTM = -548.8m USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 259.5m USD (from shortTermDebt, last quarter)
Debt = 2.87b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.73b USD (from netDebt column, last quarter)
Enterprise Value = 3.51b USD (776.7m + Debt 2.87b - CCE 140.4m)
Interest Coverage Ratio = -5.35 (Ebit TTM -996.6m / Interest Expense TTM 186.4m)
EV/FCF = -46.69x (Enterprise Value 3.51b / FCF TTM -75.2m)
FCF Yield = -2.14% (FCF TTM -75.2m / Enterprise Value 3.51b)
FCF Margin = -2.83% (FCF TTM -75.2m / Revenue TTM 2.66b)
Net Margin = -45.57% (Net Income TTM -1.21b / Revenue TTM 2.66b)
Gross Margin = 44.96% ((Revenue TTM 2.66b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 42.56% (prev 44.28%)
Tobins Q-Ratio = 0.62 (Enterprise Value 3.51b / Total Assets 5.63b)
Interest Expense / Debt = 1.78% (Interest Expense 51.1m / Debt 2.87b)
Taxrate = 21.0% (US default 21%)
NOPAT = -787.3m (EBIT -996.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.43 (Total Current Assets 1.38b / Total Current Liabilities 962.4m)
Debt / Equity = 1.55 (Debt 2.87b / totalStockholderEquity, last quarter 1.85b)
Debt / EBITDA = -4.98 (negative EBITDA) (Net Debt 2.73b / EBITDA -548.8m)
Debt / FCF = -36.36 (negative FCF - burning cash) (Net Debt 2.73b / FCF TTM -75.2m)
Total Stockholder Equity = 2.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -20.03% (Net Income -1.21b / Total Assets 5.63b)
RoE = -56.31% (Net Income TTM -1.21b / Total Stockholder Equity 2.15b)
RoCE = -21.62% (EBIT -996.6m / Capital Employed (Equity 2.15b + L.T.Debt 2.46b))
RoIC = -16.40% (negative operating profit) (NOPAT -787.3m / Invested Capital 4.80b)
WACC = 3.46% (E(776.7m)/V(3.65b) * Re(11.08%) + D(2.87b)/V(3.65b) * Rd(1.78%) * (1-Tc(0.21)))
Discount Rate = 11.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.41 | Cagr: 0.59%
[DCF] Fair Price = unknown (Cash Flow -75.2m)
EPS Correlation: -72.47 | EPS CAGR: -56.78% | SUE: -2.69 | # QB: -1
Revenue Correlation: -41.72 | Revenue CAGR: 0.28% | SUE: -1.38 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.01 | Chg30d=-89.38% | Revisions=-20% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.84 | Chg30d=+22.64% | Revisions=+43% | Analysts=5
EPS current Year (2026-12-31): EPS=1.89 | Chg30d=-12.53% | Revisions=-43% | GrowthEPS=-10.9% | GrowthRev=-0.6%
EPS next Year (2027-12-31): EPS=2.44 | Chg30d=-18.16% | Revisions=-50% | GrowthEPS=+29.2% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: -50%